Helena K. Grannis’ practice focuses disclosure and corporate governance, as well as corporate and financial transactions, particularly capital market transactions.
Her work spans numerous industries, including airlines, aviation and aerospace; automotive; consumer products and retail; banking and financial institutions; and pharmaceuticals and biotechnology.
Helena joined the firm in 2000 and became counsel in 2012.
Regularly advises clients on corporate governance and disclosure matters, including for Albany International, Allergan, Honeywell, HSBC USA, MDC Partners, Polaris, Post Holdings, and Tronox.
Honeywell in the spin-off of its home automation solutions business, and in multiple registered bond and exempt bond offerings totaling over $10 billion, and a bond concurrent abbreviated cash tender offer, and over €7 billion in Eurobond offerings.
Cushman & Wakefield and its principal shareholders in the company’s $765 million initial public offering and multiple follow-on offerings and its inaugural secured notes offering.
TPG Specialty Lending in its $112 million initial public offering and concurrent $50 million private placement, in an approximately $74 million follow-on offering, and in over $300 million of senior and convertible notes offerings.
The carve-out and sale of Surgical Care Affiliates of HealthSouth to a leading private investment firm, and in its subsequent $270 million initial public offering.
Copa Holdings in a $350 million offering of convertible senior notes in a private offering to qualified institutional buyers.
Biomet in its proposed initial public offering and Biomet, Goldman Sachs PIA, and KKR among other financial institutions in the $13.35 billion sale of Biomet to Zimmer Holdings; and subsequent secondary sales by the consortium.
Hellman & Friedman as stockholders in the SEC-registered IPO of Artisan Partners Asset Management and SEC-registered secondary offerings.
HSBC in several SEC-registered notes offerings, totaling more than $8 billion.
BNP Paribas in multiple unregistered notes offerings, totaling more than $10 billion.
Allergan in its $30 billion three-part offering in connection with its $70.5 billion acquisition of a pharmaceutical company; in the company’s structured accelerated share repurchase of $10 billion of outstanding shares; in its concurrent bond offering and tender offer; and in multiple bond offerings.
The Hartford on multiple high-profile matters, including the $2.5 billion capital investment by Allianz and the $3.3 billion capital raise to repay TARP funds, and on securities regulatory, disclosure, and corporate governance matters.
The underwriters, structuring agents, and dealer managers in a series of capital markets transactions by AIG totaling over $10 billion.
- Member, Committee on Securities Regulation, New York City Bar Association
- Staff member, United States Senate Committee on Banking, Housing and Urban Affairs, 1995 to 1997